Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “oncology” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 189
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 189 pipeline programs matching "oncology" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

189 results for “oncology” Back to intelligence hub

Search results

Page 8 of 8
  1. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial
  2. questionnaires

    Cardiff Oncology

    Anxiety

    phase 1 other active

    1 trial
  3. ziftomenib

    Kura Oncology

    Gastrointestinal Stromal Tumor (GIST)

    phase 1 small molecule active

    1 trial
  4. Atenolol

    Cardiff Oncology

    Marfan Syndrome

    approved small molecule completed

    1 trial
  5. Bimatoprost

    Cardiff Oncology

    Graves' Ophthalmopathy

    approved small molecule completed

    1 trial
  6. Carvedilol

    Cardiff Oncology

    Cirrhosis, Liver

    approved small molecule active

    1 trial
  7. Carvedilol

    Cardiff Oncology

    Cirrhoses, Liver

    approved small molecule active

    1 trial
  8. Folic Acid

    Cardiff Oncology

    Depression

    approved small molecule completed

    1 trial
  9. Pharmacokinetic based dosage change

    Cardiff Oncology

    Severe Haemophilia A

    approved small molecule completed

    1 trial
  10. Synacthen (Tetracosactrin)

    Cardiff Oncology

    Healthy

    approved small molecule completed

    1 trial
  11. Toripalimab

    Coherus Oncology

    Nasopharyngeal Cancer Recurrent

    approved small molecule active

    1 trial
  12. ketamine

    Cardiff Oncology

    Healthy Volunteers

    approved small molecule completed

    1 trial
  13. Aspirin

    Cardiff Oncology

    Platelet Dysfunction Due to Aspirin

    small molecule completed

    1 trial
  14. Fertility Health Screening

    Cardiff Oncology

    Fertility Awareness

    other completed

    1 trial
  15. MRI head

    Cardiff Oncology

    Cystic Fibrosis

    other completed

    1 trial
  16. OCT

    Cardiff Oncology

    AMD

    other active

    1 trial
  17. Oral Stimulant Drink

    Cardiff Oncology

    Volatile Organic Compounds

    other active

    1 trial
  18. PET imaging

    Cardiff Oncology

    Pituitary Adenoma

    other active

    1 trial
  19. Personalized Functional Profiling

    Universal Integrated

    Oncology

    other completed

    1 trial
  20. Urodynamics

    Cardiff Oncology

    Lower Urinary Tract Symptoms

    other completed

    1 trial
  21. Vitamin C

    CHAMPIONS ONCOLOGY, INC.

    Fontan Procedure

    other completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.